CML patients on imatinib have similar mortality rates to general population

Patients taking imatinib (Gleevec) for CML, or chronic myelogenous leukemia, and in remission after two years of treatment, have a mortality rate similar to that of the general population according to a study published online [date] in the Journal of the National Cancer Institute.

Read the whole article on Physorg

More from Physorg